A study focusing on JmjC KDMs in tauopathies reports expression levels of FBXL11 (KDM2A), JMJD1A/B (KDM3A/B), and JMJD2A/B (KDM4A/B) are substantially higher in post mortem prefrontal cortex tissue from patients with AD compared to controls, whereas FBXL10 (KDM2B) mRNA levels are downregulated in the AD patient brain.115. This evidence concerns the gene KDM3A and tauopathy.